Our gene therapy is based on E2F4, a protein involved in regulating various brain pathways representing a promising approach for a disease affecting 50 million people worldwide, with no effective treatment.
Tetraneuron’s research is centered around E2F4, a protein involved in regulating various brain pathways
Tetraneuron is investigating E2F4 phosphorylation during the earliest stages of Alzheimer’s disease, studying the presence of phosphorylated E2F4 in blood serum as an early indicator of this condition. This technology has been internationally patented.
Our focus is on developing gene therapies for neurodegenerative diseases where E2F4 plays a pivotal role in regulating processes related to inflammation, oxidative stress, and cell death. Our gene therapies aim to decelerate the progression of these disruptions by safeguarding brain cells.
We have close collaborations with prominent scientific institutions in the field of neurodegenerative diseases. These partnerships allow us to tap into a broad network of knowledge and resources to advance research and develop cutting-edge therapies.
From the beginning, Tetraneuron has been engaged in several high-value-added research projects
Tetraneuron has been granted support by the Madrid regional Goverment for an Industrial Doctorate from 2023 to 2026
The project ‘E2F4DN as a gerotherapeutic agent for brain aging’ (GeroE2F4DN), funded by the Ministry of Science and Innovation within the scope of grants for projects in strategic lines, part of the state plan for scientific, technical, and innovation research 2021-2023, under the recovery, transformation, and resilience plan 2022, aims to evaluate E2F4DN as a gerotherapeutic agent
The project with file number IMIDTA/2022/77 entitled “Characterization of new tools for studying the efficacy of gene therapies against glaucoma,” with a total budget of €145,730, has received a grant of €65,578.50.
This initiative, focused on enhancing knowledge about this condition, marks a new path forward for Tetraneuron in the development of innovative gene therapies for neurodegenerative diseases.
Tetraneuron has been granted support for the completion of an Industrial Doctorate under the project “Therapeutic Potential of E2F4DN in Alzheimer’s Disease: Analysis of its Neuroimmunomodulatory Effect”
Torres Quevedo Incorpora Grant for the recruitment of a researcher for the development of an industrial research project
